What is Nevro?
Founded in 2006 and headquartered in Redwood City, California, Nevro is a specialized medical device company dedicated to improving the quality of life for patients with chronic pain. The company is best known for its innovative neuromodulation platforms, which provide non-opioid alternatives for pain management. By integrating advanced clinical research with sophisticated engineering, Nevro has established itself as a critical provider in the healthcare ecosystem, bridging the gap between complex neurological science and practical clinical application.
How much funding has Nevro raised?
Nevro has raised a total of $921.8M across 10 funding rounds:
Series A
$22M
Series B
$58M
Series C
$48M
Stock Offering
$131M
Debt
$20M
Stock Offering
$118M
Debt
$172.5M
Stock Offering
$157M
Debt
$189.8M
Series A (2008): $22M led by Aberdare Ventures, MPM Capital, Mayo Clinic, Accuitive Medical Ventures, Three Arch Partners, and Bay City Capital
Series B (2011): $58M supported by MPM Capital, Aberdare Ventures, Accuitive Medical Ventures, Three Arch Partners, Mayo Clinic, Bay City Capital, and Johnson & Johnson Development Corporation
Series C (2013): $48M featuring Mayo Clinic, New Enterprise Associates, Johnson & Johnson Development Corporation, MPM Capital, Accuitive Medical Ventures, Three Arch Partners, Bay City Capital, Covidien Ventures, and Novo Ventures
Stock Issuance/Offering (2014): $131M backed by Undisclosed
Debt (2014): $20M with participation from CRG
Stock Issuance/Offering (2015): $118M led by Undisclosed
Debt (2016): $172.5M supported by Undisclosed
Stock Issuance/Offering (2020): $157M featuring Undisclosed
Debt (2020): $189.8M backed by Undisclosed
Key Investors in Nevro
Aberdare Ventures
Aberdare Ventures is a leading venture capital firm that specializes in investing in transformational companies aimed at enhancing healthcare efficiency and reducing costs.
Mayo Clinic
Mayo Clinic is a nonprofit global healthcare organization specializing in integrated clinical practice, education, and medical research.
Bay City Capital
Bay City Capital is a venture capital firm founded in 1997 that specializes in investing in life sciences.
What's next for Nevro?
Looking ahead, the strategic deployment of the $157M capital is expected to accelerate Nevro's research and development pipeline. As the company scales, the focus will likely shift toward expanding its clinical footprint and enhancing its market penetration in the global pain management sector. Given its history of securing backing from top-tier life sciences investors, Nevro is well-positioned to leverage its current liquidity to explore new therapeutic indications and optimize its existing product portfolio, thereby maintaining its competitive edge in a rapidly evolving medical technology market.
See full Nevro company page
